One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient
Filippo Crea
doi : 10.1093/eurheartj/ehad181
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1099–1102
Exploring disease which does not exist
Peter Lanzer
doi : 10.1093/eurheartj/ehac622
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1103–1104
Heart rate variability and heart rate patterns measured from wearable and implanted devices in screening for atrial fibrillation: potential clinical and population-wide applications
Patrycja S Matusik, Paweł T Matusik, Phyllis K Stein
doi : 10.1093/eurheartj/ehac546
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1105–1107
In memoriam: Professor Carmen Ginghină
Bogdan A Popescu
doi : 10.1093/eurheartj/ehac619
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1108–1109
The ‘cold case’ of chlortalidone vs. hydrochlorothiazide in hypertension closed by the diuretic comparison project?
Massimo Volpe, Giovanna Liuzzo
doi : 10.1093/eurheartj/ehad077
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1110–1111
Prevention of cardiorenal damage: importance of albuminuria
Luis M Ruilope, Alberto Ortiz, Alejandro Lucia, Blanca Miranda, Gloria Alvarez-Llamas, Maria G Barderas, Massimo Volpe, Gema Ruiz-Hurtado, Bertram Pitt
doi : 10.1093/eurheartj/ehac683
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1112–1123
Chronic kidney disease (CKD) is projected to become a leading global cause of death by 2040, and its early detection is critical for effective and timely management. The current definition of CKD identifies only advanced stages, when kidney injury has already destroyed >50% of functioning kidney mass as reflected by an estimated glomerular filtration rate <60 mL/min/1.73 m2 or a urinary albumin/creatinine ratio >six-fold higher than physiological levels (i.e. > 30 mg/g).
Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study
Jonas Bruhn, Morten Malmborg, Caroline H Garred, Pauline Ravn, Deewa Zahir, Charlotte Andersson, Gunnar Gislason, Christian Torp-Pedersen, Kristian Kragholm, Emil Fosbol, Jawad H Butt, Ninian N Lang, Mark C Petrie, John McMurray, Lars Kober, Morten Schou
doi : 10.1093/eurheartj/ehac797
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1124–1132
Cancer and heart failure (HF) share risk factors, pathophysiological mechanisms, and possibly genetics. Improved HF survival may increase the risk of cancer due to a competing risk. Whether the incidence of cancer has increased over time in patients with HF as survival has improved is unclear. Therefore, temporal trends of new onset cancer in HF patients between 1997 and 2016 were investigated.
Cancer is a comorbidity of heart failure
Pietro Ameri, Edoardo Bertero, Wouter C Meijers
doi : 10.1093/eurheartj/ehac710
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1133–1135
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
Jawad H Butt, Mark C Petrie, Pardeep S Jhund, Naveed Sattar, Akshay S Desai, Lars Køber, Jean L Rouleau, Karl Swedberg, Michael R Zile, Scott D Solomon, Milton Packer, John J V McMurray
doi : 10.1093/eurheartj/ehad083
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1136–1153
Although body mass index (BMI) is the most commonly used anthropometric measure, newer indices such as the waist-to-height ratio, better reflect the location and amount of ectopic fat, as well as the weight of the skeleton, and may be more useful.
Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
Ryosuke Sato, Stephan von Haehling
doi : 10.1093/eurheartj/ehad079
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1154–1156
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study
Patrick B Mark, Juan J Carrero, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Morgan E Grams, Josef Coresh, Aditya Surapaneni, Nigel J Brunskill, John Chalmers, Lili Chan, Alex R Chang, Rajkumar Chinnadurai, Gabriel Chodick, Massimo Cirillo, Dick de Zeeuw, Marie Evans, Amit X Garg, Orlando M Gutierrez, Hiddo J L Heerspink, Gunnar H Heine, William G Herrington, Junichi Ishigami, Florian Kronenberg, Jun Young Lee, Adeera Levin, Rupert W Major, Angharad Marks, Girish N Nadkarni, David M J Naimark, Christoph Nowak, Mahboob Rahman, Charumathi Sabanayagam, Mark Sarnak, Simon Sawhney, Markus P Schneider, Varda Shalev, Jung-Im Shin, Moneeza K Siddiqui, Nikita Stempniewicz, Keiichi Sumida, José M Valdivielso, Jan van den Brand, Angela Yee-Moon Wang, David C Wheeler, Lihua Zhang, Frank L J Visseren, Benedicte Stengel
doi : 10.1093/eurheartj/ehac825
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1157–1166
Chronic kidney disease (CKD) increases risk of cardiovascular disease (CVD). Less is known about how CVD associates with future risk of kidney failure with replacement therapy (KFRT).
The cardiovascular–renal link and the health burden of kidney failure
Carmine Zoccali, Francesca Mallamaci
doi : 10.1093/eurheartj/ehad039
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1167–1169
Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration
Edgar E Nollet, Inez Duursma, Anastasiya Rozenbaum, Moritz Eggelbusch, Rob C I Wüst, Stephan A C Schoonvelde, Michelle Michels, Mark Jansen, Nicole N van der Wel, Kenneth C Bedi, Jr, Kenneth B Margulies, Jeff Nirschl, Diederik W D Kuster, Jolanda van der Velden
doi : 10.1093/eurheartj/ehad028
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1170–1185
Genetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial dysfunction is thought to be a key driver of pathological remodelling in HCM. Reports of mitochondrial respiratory function and specific disease-modifying treatment options in patients with HCM are scarce.
Targeting mitochondria in hypertrophic cardiomyopathy
Vasco Sequeira, Angelika Batzner, Christoph Maack
doi : 10.1093/eurheartj/ehad081
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Pages 1186–1188
3D-rendered computed tomography imaging support the diagnosis and strategic decision-making: a rare case of acute pulmonary thromboembolism presenting with thrombus straddling a patent foramen ovale
Chika Matsushita, Mahoto Inatsu, Hideki Tanaka
doi : 10.1093/eurheartj/ehac498
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Page 1189
Fatty abdominal aortic aneurysm
Chuanqi Cai, Yi Guo, Weici Wang
doi : 10.1093/eurheartj/ehac678
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Page 1190
Remarkable regression of diffuse coronary atherosclerosis in patients with triglyceride deposit cardiomyovasculopathy
Ken-ichi Hirano, Masahiro Higashi, Kenichi Nakajima
doi : 10.1093/eurheartj/ehac762
European Heart Journal, Volume 44, Issue 13, 1 April 2023, Page 1191
Focus issue on vascular biology and medicine spanning from management of stroke to new therapeutic targets in aortic dissection and pulmonary hypertension
Filippo Crea
doi : 10.1093/eurheartj/ehad198
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1193–1196
Small country big difference: how one physician’s vision became a reality and transformed acute myocardial infarction management in the Republic of Mauritius
Judith Ozkan
doi : 10.1093/eurheartj/ehad012
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1197–1198
Cardio-oncological evaluation and management of patients in China
Yaling Han
doi : 10.1093/eurheartj/ehad064
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1199–1200
Rising stars: Lorena Montes Villalobos
Judith Ozkan
doi : 10.1093/eurheartj/ehac724
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1201–1202
Intravenous ferric derisomaltose for patients with heart failure: does iron heart translate into IRONMAN?
Rocco Vergallo, Daniela Pedicino
doi : 10.1093/eurheartj/ehad076
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1203–1204
Acute ischaemic stroke: recent advances in reperfusion treatment
Petr Widimsky, Kenneth Snyder, Jakub Sulzenko, Leo Nelson Hopkins, Ivana Stetkarova
doi : 10.1093/eurheartj/ehac684
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1205–1215
During the last 5–7 years, tremendous progress was achieved in the reperfusion treatment of acute ischaemic stroke during its first few hours from symptom onset.
Translational opportunities of single-cell biology in atherosclerosis
Menno P J de Winther, Magnus Bäck, Paul Evans, Delphine Gomez, Isabel Goncalves, Helle F Jørgensen, Rory R Koenen, Esther Lutgens, Giuseppe Danilo Norata, Elena Osto, Lea Dib, Michael Simons, Konstantinos Stellos, Seppo Ylä-Herttuala, Holger Winkels, Marie-Luce Bochaton-Piallat, Claudia Monaco
doi : 10.1093/eurheartj/ehac686
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1216–1230
The advent of single-cell biology opens a new chapter for understanding human biological processes and for diagnosing, monitoring, and treating disease.
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
Maria A de Winter, Harry R Büller, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Gary E Raskob, Henrik T Sørensen, Frank L J Visseren, Philip S Wells, Jannick A N Dorresteijn, Mathilde Nijkeuter, VTE-PREDICT study group
doi : 10.1093/eurheartj/ehac776
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1231–1244
Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally validate models for predicting 5-year risks of recurrence and bleeding in patients with VTE without cancer who completed at least 3 months of initial treatment, which can be used to estimate individual absolute benefits and harms of extended anticoagulation.
Walking the tightrope: a balanced discussion of the benefits and harms of extended duration anticoagulation for venous thrombo-embolism
Gregory Piazza
doi : 10.1093/eurheartj/ehac731
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1245–1247
Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection
Xueyuan Yang, Chen Xu, Fang Yao, Qianhui Ding, Hao Liu, Congcong Luo, Daidai Wang, Jiaqi Huang, Zhiqing Li, Yicong Shen, Weijie Yang, Zhuofan Li, Fang Yu, Yi Fu, Li Wang, Qingbian Ma, Junming Zhu, Fujian Xu, Xin Cong, Wei Kong
doi : 10.1093/eurheartj/ehac823
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1248–1261
Whether changes in endothelial tight junctions (TJs) lead to the formation of thoracic aortic aneurysm and dissection (TAAD) and serve as an early indicator and therapeutic target remains elusive.
The emerging role of endothelial cells in the pathogenesis of thoracic aortic aneurysm and dissection
Aline Verstraeten, Ivanna Fedoryshchenko, Bart Loeys
doi : 10.1093/eurheartj/ehac771
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1262–1264
Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models
Qian Ma, Qiuhua Yang, Jiean Xu, Hunter G Sellers, Zach L Brown, Zhiping Liu, Zsuzsanna Bordan, Xiaofan Shi, Dingwei Zhao, Yongfeng Cai, Vidhi Pareek, Chunxiang Zhang, Guangyu Wu, Zheng Dong, Alexander D Verin, Lin Gan, Quansheng Du, Stephen J Benkovic, Suowen Xu, John M Asara, Issam Ben-Sahra, Scott Barman, Yunchao Su, David J R Fulton, Yuqing Huo
doi : 10.1093/eurheartj/ehad044
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1265–1279
Proliferation of vascular smooth muscle cells (VSMCs) is a hallmark of pulmonary hypertension (PH). Proliferative cells utilize purine bases from the de novo purine synthesis (DNPS) pathways for nucleotide synthesis; however, it is unclear whether DNPS plays a critical role in VSMC proliferation during development of PH.
De novo purine synthesis: a new target in pulmonary arterial hypertension?
Gayathri Viswanathan, Sudarshan Rajagopal
doi : 10.1093/eurheartj/ehad078
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Pages 1280–1282
Chronic concomitant pulmonary artery and aortic dissection following patent ductus arteriosus occlusion surgery
Heng Zhang, Xin Chen, Xue-lian Ao, Liang Ma
doi : 10.1093/eurheartj/ehac745
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Page 1283
Left internal thoracic artery bypass graft
Kentaro Mitsui, Masashi Fujino, Teruo Noguchi
doi : 10.1093/eurheartj/ehad073
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Page 1284
A case of Takayasu’s arteritis and thoracic-abdominal pseudoaneurysm with vertebral destruction
Bo Jiang, Jingyu Li, Hao Tang
doi : 10.1093/eurheartj/ehad074
European Heart Journal, Volume 44, Issue 14, 7 April 2023, Page 1285
